This schematic illustrates how the gut–brain axis may contribute to the spread of alpha-synuclein pathology in Parkinson’s disease (adapted from Breen et al., 2019).
Researchers have proposed that gut inflammation, increased intestinal permeability, and changes in the gut microbiome may drive or promote this process.
Related content
Possible α-synuclein targets for development of therapies for Parkinson’s disease
Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease
26.06.2025
Parkinson’s Disease
Disease modification in Parkinson’s disease
Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure
26.06.2025
Parkinson’s Disease
Catechol-O-methyltransferase (COMT) inhibitors: mechanism of action
Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA
26.06.2025
Parkinson’s Disease